Repression of breast cancer cell growth by proteasome inhibitors in vitro: impact of mitogen-activated protein kinase phosphatase 1

References

• Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352:2487-98; PMID:15958804; http://dx.doi.org/10.1056/NEJMoa043445
   PubMed Web of Science ®Google Scholar
• Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, Epner E, Krishnan A, Leonard JP, Lonial S, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006; 24:4867-74; PMID:17001068; http://dx.doi.org/10.1200/JCO.2006.07.9665
   PubMed Web of Science ®Google Scholar
• Cvek B. Proteasome inhibitors. Prog Mol Biol Transl Sci 2012; 109:161-226; PMID:22727422; http://dx.doi.org/10.1016/B978-0-12-397863-9.00005-5
   PubMed Web of Science ®Google Scholar
• McConkey DJ, Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat 2008; 11:164-79; PMID:18818117; http://dx.doi.org/10.1016/j.drup.2008.08.002
   PubMed Web of Science ®Google Scholar
• Small GW, Shi YY, Edmund NA, Somasundaram S, Moore DT, Orlowski RZ. Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role. Mol Pharmacol 2004; 66:1478-90; PMID:15448190; http://dx.doi.org/10.1124/mol.104.003400
   PubMed Web of Science ®Google Scholar
• Shi YY, Small GW, Orlowski RZ. Proteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer. Breast Cancer Res Treat 2006; 100:33-47; PMID:16807678; http://dx.doi.org/10.1007/s10549-006-9232-x
   PubMed Web of Science ®Google Scholar
• Small GW, Shi YY, Higgins LS, Orlowski RZ. Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance. Cancer Res 2007; 67:4459-66; PMID:17483361; http://dx.doi.org/10.1158/0008-5472.CAN-06-2644
   PubMed Web of Science ®Google Scholar
• Haagenson KK, Wu GS. The role of MAP kinases and MAP kinase phosphatase-1 in resistance to breast cancer treatment. Cancer Metastasis Rev 2010; 29:143-9; PMID:20111893; http://dx.doi.org/10.1007/s10555-010-9208-5
   PubMed Web of Science ®Google Scholar
• Rojo F, Gonzalez-Navarrete I, Bragado R, Dalmases A, Menendez S, Cortes-Sempere M, Suárez C, Oliva C, Servitja S, Rodriguez-Fanjul V, et al. Mitogen-activated protein kinase phosphatase-1 in human breast cancer independently predicts prognosis and is repressed by doxorubicin. Clin Cancer Res 2009; 15:3530-9; PMID:19417026; http://dx.doi.org/10.1158/1078-0432.CCR-08-2070
   PubMed Web of Science ®Google Scholar
• Sun H, Charles CH, Lau LF, Tonks NK. MKP-1 (3CH134), an immediate early gene product, is a dual specificity phosphatase that dephosphorylates MAP kinase in vivo. Cell 1993; 75:487-93; PMID:8221888; http://dx.doi.org/10.1016/0092-8674(93)90383-2
   PubMed Web of Science ®Google Scholar
• Che W, Manetsch M, Quante T, Rahman MM, Patel BS, Ge Q, Ammit AJ. Sphingosine 1-phosphate induces MKP-1 expression via p38 MAPK- and CREB-mediated pathways in airway smooth muscle cells. Biochim Biophys Acta 2012; 1823:1658-65; PMID:22743041; http://dx.doi.org/10.1016/j.bbamcr.2012.06.011
   PubMed Web of Science ®Google Scholar
• Manetsch M, Che W, Seidel P, Chen Y, Ammit AJ. MKP-1: a negative feedback effector that represses MAPK-mediated pro-inflammatory signaling pathways and cytokine secretion in human airway smooth muscle cells. Cell Signal 2012; 24:907-13; PMID:22200679; http://dx.doi.org/10.1016/j.cellsig.2011.12.013
   PubMed Web of Science ®Google Scholar
• Doddareddy MR, Rawling T, Ammit AJ. Targeting mitogen-activated protein kinase phosphatase-1 (MKP-1): structure-based design of MKP-1 inhibitors and upregulators. Curr Med Chem 2012; 19:163-73; PMID:22320295; http://dx.doi.org/10.2174/092986712803414196
   PubMed Web of Science ®Google Scholar
• Hu JH, Chen T, Zhuang ZH, Kong L, Yu MC, Liu Y, Zang JW, Ge BX. Feedback control of MKP-1 expression by p38. Cell Signal 2007; 19:393-400; PMID:16978838; http://dx.doi.org/10.1016/j.cellsig.2006.07.010
   PubMed Web of Science ®Google Scholar
• Chen P, Li J, Barnes J, Kokkonen GC, Lee JC, Liu Y. Restraint of proinflammatory cytokine biosynthesis by mitogen-activated protein kinase phosphatase-1 in lipopolysaccharide-stimulated macrophages. J Immunol 2002; 169:6408-16; PMID:12444149; http://dx.doi.org/10.4049/jimmunol.169.11.6408
   PubMed Web of Science ®Google Scholar
• Zhao Q, Shepherd EG, Manson ME, Nelin LD, Sorokin A, Liu Y. The role of mitogen-activated protein kinase phosphatase-1 in the response of alveolar macrophages to lipopolysaccharide: attenuation of proinflammatory cytokine biosynthesis via feedback control of p38. J Biol Chem 2005; 280:8101-8; PMID:15590669; http://dx.doi.org/10.1074/jbc.M411760200
   PubMed Web of Science ®Google Scholar
• Tai C-J, Wu AT, Chiou J-F, Jan H-J, Wei H-J, Hsu C-H, Lin CT, Chiu WT, Wu CW, Lee HM, et al. The investigation of Mitogen-Activated Protein kinase Phosphatase-1 as a potential pharmacological target in non-small cell lung carcinomas, assisted by non-invasive molecular imaging. BMC Cancer 2010; 10:1-14; PMID:20226009; http://dx.doi.org/10.1186/1471-2407-10-95
   PubMed Web of Science ®Google Scholar
• Kang DW, Lee JY, Oh DH, Park SY, Woo TM, Kim MK, Park MH, Jang YH, Min do S. Triptolide-induced suppression of phospholipase D expression inhibits proliferation of MDA-MB-231 breast cancer cells. Exp Mol Med 2009; 41:678-85; PMID:19478552; http://dx.doi.org/10.3858/emm.2009.41.9.074
   PubMed Web of Science ®Google Scholar
• Liu J, Jiang Z, Xiao J, Zhang Y, Lin S, Duan W, Yao J, Liu C, Huang X, Wang T, et al. Effects of triptolide from Tripterygium wilfordii on ERalpha and p53 expression in two human breast cancer cell lines. Phytomedicine 2009; 16:1006-13; PMID:19524422; http://dx.doi.org/10.1016/j.phymed.2009.03.021
   PubMed Web of Science ®Google Scholar
• Lu L, Kanwar J, Schmitt S, Cui QC, Zhang C, Zhao C, Dou QP. Inhibition of tumor cellular proteasome activity by triptolide extracted from the Chinese medicinal plant 'thunder god vine'. Anticancer Res 2011; 31:1-10; PMID:21273574
   PubMed Web of Science ®Google Scholar
• Bensaude O. Inhibiting eukaryotic transcription: Which compound to choose? How to evaluate its activity? Transcription 2011; 2:103-8; PMID:21922053; http://dx.doi.org/10.4161/trns.2.3.16172
   PubMedGoogle Scholar
• Marderosian M, Sharma A, Funk AP, Vartanian R, Masri J, Jo OD, Gera JF. Tristetraprolin regulates Cyclin D1 and c-Myc mRNA stability in response to rapamycin in an Akt-dependent manner via p38 MAPK signaling. Oncogene 2006; 25:6277-90; PMID:16702957; http://dx.doi.org/10.1038/sj.onc.1209645
   PubMed Web of Science ®Google Scholar
• Yang CH, Gonzalez-Angulo AM, Reuben JM, Booser DJ, Pusztai L, Krishnamurthy S, Esseltine D, Stec J, Broglio KR, Islam R, et al. Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. Ann Oncol 2006; 17:813-7; PMID:16403809; http://dx.doi.org/10.1093/annonc/mdj131
   PubMed Web of Science ®Google Scholar
• Engel RH, Brown JA, Von Roenn JH, O'Regan RM, Bergan R, Badve S, Rademaker A, Gradishar WJ. A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience. Cancer Invest 2007; 25:733-7; PMID:17952740; http://dx.doi.org/10.1080/07357900701506573
   PubMed Web of Science ®Google Scholar
• Cresta S, Sessa C, Catapano CV, Gallerani E, Passalacqua D, Rinaldi A, Bertoni F, Viganò L, Maur M, Capri G, et al. Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours. Eur J Cancer 2008; 44:1829-34; PMID:18640031; http://dx.doi.org/10.1016/j.ejca.2008.05.022
   PubMed Web of Science ®Google Scholar
• Wu W, Pew T, Zou M, Pang D, Conzen SD. Glucocorticoid receptor-induced MAPK phosphatase-1 (MPK-1) expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival. J Biol Chem 2005; 280:4117-24; PMID:15590693; http://dx.doi.org/10.1074/jbc.M411200200
   PubMed Web of Science ®Google Scholar
• Liu Q. Triptolide and its expanding multiple pharmacological functions. Int Immunopharmacol 2011; 11:377-83; PMID:21255694; http://dx.doi.org/10.1016/j.intimp.2011.01.012
   PubMed Web of Science ®Google Scholar
• Soule HD, Maloney TM, Wolman SR, Peterson WD Jr, Brenz R, McGrath CM, Russo J, Pauley RJ, Jones RF, Brooks SC. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 1990;50(18):6075-86; PMID:1975513
   PubMed Web of Science ®Google Scholar
• Basolo F, Elliott J, Tait L, Chen XQ, Maloney T, Russo IH, Pauley R, Momiki S, Caamano J, Klein-Szanto AJ, et al. Transformation of human breast epithelial cells by c-Ha-ras oncogene. Mol Carcinog 1991; 4(1):25-35; PMID:2009132
   PubMed Web of Science ®Google Scholar
• Caixeiro NJ, Martin JL, Scott CD. Silencing the mannose 6-phosphate/IGF-II receptor differentially affects tumorigenic properties of normal breast epithelial cells. Int J Cancer 2013; 133(11):2542-50; PMID:23686499
   PubMed Web of Science ®Google Scholar
• Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65:55-63; PMID:6606682; http://dx.doi.org/10.1016/0022-1759(83)90303-4
   PubMed Web of Science ®Google Scholar